What changes are being made to the Stock Trading Policy for executives and directors?

Effective July 1, 2010, Boston Scientific's Stock Trading Policy will prohibit executive officers and directors from pledging their company stock or entering into hedging arrangements. This is intended to align their interests more directly with those of long-term shareholders and reduce potential conflicts or risks associated with such financial activities.

Are there any exceptions to the new stock trading restrictions?

Yes, there are exceptions. Shares held by directors subject to pledging or hedging arrangements as of December 31, 2010, are excluded to a certain extent. Newly appointed executive officers and directors have nine months to unwind pre-existing arrangements. All such pre-existing arrangements must be disclosed upon nomination or appointment and are subject to aggregate limitations on the total percentage of outstanding shares involved.

Were there any significant outcomes from the Annual Meeting of Stockholders?

The Annual Meeting of Stockholders held on May 11, 2010, resulted in the election of all twelve director nominees to the Board. Additionally, stockholders overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2010.

BSX 8-K: Leadership Changes & Shareholder Matters

Q: What is the Boston Scientific Corporation Deferred Bonus Plan?

The Deferred Bonus Plan allows a select group of management employees to defer a portion of their annual bonus compensation. Participants can elect to defer up to 75% of their bonus, with the deferred amount payable upon termination of employment or at an elected distribution date, either as a lump sum or in annual installments over two to five years. This plan is designed to provide tax-deferred savings and retention incentives.

Summary

Boston Scientific Corporation (BSX) filed an 8-K on May 17, 2010, reporting on key corporate governance and compensation matters. The most significant development for investors is the approval of the Boston Scientific Corporation Deferred Bonus Plan, which allows select management personnel to defer a portion of their annual bonus compensation. This plan offers flexibility in deferral amounts (up to 75%) and distribution timing, with elections made annually by June 30 and distributions occurring upon termination of employment or at an elected date, in lump sums or installments over two to five years. Additionally, the company announced an amendment to its Stock Trading Policy, effective July 1, 2010, which prohibits executive officers and directors from pledging company stock or entering into hedging arrangements. This move aims to enhance corporate governance and align executive interests more closely with those of shareholders. Furthermore, the filing details the outcomes of the company's Annual Meeting of Stockholders held on May 11, 2010. All twelve director nominees were elected, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2010, was ratified by a substantial majority of votes. These events reflect the company's ongoing efforts in board refreshment, executive compensation structuring, and adherence to robust financial oversight.

Key Highlights

1Approval of the Boston Scientific Corporation Deferred Bonus Plan, allowing eligible management to defer up to 75% of their annual bonus.
2Deferred bonus distributions can be lump sum or installments over 2-5 years, triggered by termination or elected date.
3Stock Trading Policy amended to prohibit executive officers and directors from pledging or hedging company stock, effective July 1, 2010.
4Exemptions for existing pledging/hedging arrangements for directors and executive officers, subject to specific limitations and disclosure requirements.
5All twelve director nominees were elected at the May 11, 2010 Annual Meeting of Stockholders.
6Ernst & Young LLP ratified as the independent registered public accounting firm for fiscal year 2010.
7The filing addresses routine corporate governance matters and compensation adjustments relevant to executive and director behavior.

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (May 17, 2010)

Summary

Key Highlights

Frequently Asked Questions